ANDA 214344, held by Hetero Labs Ltd V. Atorvastatin Calcium.
As of Nov 16, 2026, ANDA 214344 (Atorvastatin Calcium), held by Hetero Labs Ltd V, was first approved by FDA on Sep 12, 2023, with 1 approved supplement and 0 published complete response letters.
Atorvastatin calcium tablets are indicated:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 12, 2023 | Original application | Approved | None posted |
| Atorvastatin CalciumEQ 10MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 20MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 40MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 80MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Jun 14, 2024 | Supplement 9Labeling · Standard review | Approved | None posted |
| Sep 12, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters